Primary mediastinal B-cell lymphoma: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Primary mediastinal B-cell lymphoma | |||
| image = [[File:Primary_mediastinal_large_B-cell_lymphoma_-_very_high_mag.jpg|alt=Micrograph of primary mediastinal large B-cell lymphoma]] | |||
| caption = Micrograph of primary mediastinal large B-cell lymphoma | |||
| field = [[Hematology]] | |||
| symptoms = [[Cough]], [[chest pain]], [[dyspnea]] | |||
| complications = [[Superior vena cava syndrome]], [[pleural effusion]] | |||
| onset = Typically in young adults | |||
| duration = Variable | |||
| causes = Unknown | |||
| risks = [[Female]] gender, [[young adulthood]] | |||
| diagnosis = [[Biopsy]], [[imaging studies]] | |||
| differential = [[Hodgkin lymphoma]], [[thymoma]], [[germ cell tumor]] | |||
| treatment = [[Chemotherapy]], [[radiation therapy]] | |||
| prognosis = Generally favorable with treatment | |||
| frequency = Rare | |||
}} | |||
{{Short description|A type of non-Hodgkin lymphoma}} | {{Short description|A type of non-Hodgkin lymphoma}} | ||
'''Primary mediastinal B-cell lymphoma''' (PMBCL) is a subtype of [[diffuse large B-cell lymphoma]] (DLBCL), which is a type of [[non-Hodgkin lymphoma]]. It is characterized by the presence of a mass in the [[mediastinum]], the central compartment of the thoracic cavity. PMBCL primarily affects young adults, with a higher prevalence in females. | '''Primary mediastinal B-cell lymphoma''' (PMBCL) is a subtype of [[diffuse large B-cell lymphoma]] (DLBCL), which is a type of [[non-Hodgkin lymphoma]]. It is characterized by the presence of a mass in the [[mediastinum]], the central compartment of the thoracic cavity. PMBCL primarily affects young adults, with a higher prevalence in females. | ||
==Pathophysiology== | ==Pathophysiology== | ||
PMBCL originates from B-cells, a type of [[white blood cell]] that plays a crucial role in the immune response. These B-cells undergo malignant transformation and proliferate uncontrollably, forming a tumor in the mediastinum. The exact cause of this transformation is not fully understood, but it involves genetic mutations and alterations in signaling pathways that regulate cell growth and survival. | PMBCL originates from B-cells, a type of [[white blood cell]] that plays a crucial role in the immune response. These B-cells undergo malignant transformation and proliferate uncontrollably, forming a tumor in the mediastinum. The exact cause of this transformation is not fully understood, but it involves genetic mutations and alterations in signaling pathways that regulate cell growth and survival. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
Patients with PMBCL typically present with symptoms related to the mass effect of the tumor in the mediastinum. Common symptoms include: | Patients with PMBCL typically present with symptoms related to the mass effect of the tumor in the mediastinum. Common symptoms include: | ||
| Line 12: | Line 27: | ||
* [[Chest pain]] | * [[Chest pain]] | ||
* [[Superior vena cava syndrome]], which results from compression of the superior vena cava and leads to swelling of the face and arms, and distended neck veins. | * [[Superior vena cava syndrome]], which results from compression of the superior vena cava and leads to swelling of the face and arms, and distended neck veins. | ||
==Diagnosis== | ==Diagnosis== | ||
The diagnosis of PMBCL involves a combination of clinical evaluation, imaging studies, and histopathological examination. | The diagnosis of PMBCL involves a combination of clinical evaluation, imaging studies, and histopathological examination. | ||
===Imaging=== | ===Imaging=== | ||
Imaging studies such as [[chest X-ray]], [[computed tomography]] (CT) scan, and [[positron emission tomography]] (PET) scan are used to assess the size and extent of the mediastinal mass. | Imaging studies such as [[chest X-ray]], [[computed tomography]] (CT) scan, and [[positron emission tomography]] (PET) scan are used to assess the size and extent of the mediastinal mass. | ||
===Histopathology=== | ===Histopathology=== | ||
A biopsy of the mediastinal mass is essential for definitive diagnosis. Histopathological examination reveals large atypical B-cells with a diffuse growth pattern. Immunohistochemistry is used to confirm the B-cell origin of the tumor by demonstrating the expression of B-cell markers such as CD20. | A biopsy of the mediastinal mass is essential for definitive diagnosis. Histopathological examination reveals large atypical B-cells with a diffuse growth pattern. Immunohistochemistry is used to confirm the B-cell origin of the tumor by demonstrating the expression of B-cell markers such as CD20. | ||
==Treatment== | ==Treatment== | ||
The treatment of PMBCL typically involves a combination of [[chemotherapy]] and [[radiation therapy]]. | The treatment of PMBCL typically involves a combination of [[chemotherapy]] and [[radiation therapy]]. | ||
===Chemotherapy=== | ===Chemotherapy=== | ||
The standard chemotherapy regimen for PMBCL is R-CHOP, which includes: | The standard chemotherapy regimen for PMBCL is R-CHOP, which includes: | ||
| Line 33: | Line 42: | ||
* [[Vincristine]] | * [[Vincristine]] | ||
* [[Prednisone]] | * [[Prednisone]] | ||
===Radiation Therapy=== | ===Radiation Therapy=== | ||
Radiation therapy may be used in conjunction with chemotherapy to improve local control of the disease, especially in cases where there is residual disease after chemotherapy. | Radiation therapy may be used in conjunction with chemotherapy to improve local control of the disease, especially in cases where there is residual disease after chemotherapy. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for patients with PMBCL has improved significantly with modern treatment regimens. The overall survival rate is favorable, particularly for patients who achieve complete remission after initial therapy. | The prognosis for patients with PMBCL has improved significantly with modern treatment regimens. The overall survival rate is favorable, particularly for patients who achieve complete remission after initial therapy. | ||
==See also== | |||
== | |||
* [[Diffuse large B-cell lymphoma]] | * [[Diffuse large B-cell lymphoma]] | ||
* [[Non-Hodgkin lymphoma]] | * [[Non-Hodgkin lymphoma]] | ||
* [[Mediastinum]] | * [[Mediastinum]] | ||
[[Category:Lymphoma]] | [[Category:Lymphoma]] | ||
[[Category:Non-Hodgkin lymphoma]] | [[Category:Non-Hodgkin lymphoma]] | ||
Latest revision as of 15:25, 8 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Primary mediastinal B-cell lymphoma | |
|---|---|
| |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Cough, chest pain, dyspnea |
| Complications | Superior vena cava syndrome, pleural effusion |
| Onset | Typically in young adults |
| Duration | Variable |
| Types | N/A |
| Causes | Unknown |
| Risks | Female gender, young adulthood |
| Diagnosis | Biopsy, imaging studies |
| Differential diagnosis | Hodgkin lymphoma, thymoma, germ cell tumor |
| Prevention | N/A |
| Treatment | Chemotherapy, radiation therapy |
| Medication | N/A |
| Prognosis | Generally favorable with treatment |
| Frequency | Rare |
| Deaths | N/A |
A type of non-Hodgkin lymphoma
Primary mediastinal B-cell lymphoma (PMBCL) is a subtype of diffuse large B-cell lymphoma (DLBCL), which is a type of non-Hodgkin lymphoma. It is characterized by the presence of a mass in the mediastinum, the central compartment of the thoracic cavity. PMBCL primarily affects young adults, with a higher prevalence in females.
Pathophysiology[edit]
PMBCL originates from B-cells, a type of white blood cell that plays a crucial role in the immune response. These B-cells undergo malignant transformation and proliferate uncontrollably, forming a tumor in the mediastinum. The exact cause of this transformation is not fully understood, but it involves genetic mutations and alterations in signaling pathways that regulate cell growth and survival.
Clinical Presentation[edit]
Patients with PMBCL typically present with symptoms related to the mass effect of the tumor in the mediastinum. Common symptoms include:
- Cough
- Dyspnea (shortness of breath)
- Chest pain
- Superior vena cava syndrome, which results from compression of the superior vena cava and leads to swelling of the face and arms, and distended neck veins.
Diagnosis[edit]
The diagnosis of PMBCL involves a combination of clinical evaluation, imaging studies, and histopathological examination.
Imaging[edit]
Imaging studies such as chest X-ray, computed tomography (CT) scan, and positron emission tomography (PET) scan are used to assess the size and extent of the mediastinal mass.
Histopathology[edit]
A biopsy of the mediastinal mass is essential for definitive diagnosis. Histopathological examination reveals large atypical B-cells with a diffuse growth pattern. Immunohistochemistry is used to confirm the B-cell origin of the tumor by demonstrating the expression of B-cell markers such as CD20.
Treatment[edit]
The treatment of PMBCL typically involves a combination of chemotherapy and radiation therapy.
Chemotherapy[edit]
The standard chemotherapy regimen for PMBCL is R-CHOP, which includes:
Radiation Therapy[edit]
Radiation therapy may be used in conjunction with chemotherapy to improve local control of the disease, especially in cases where there is residual disease after chemotherapy.
Prognosis[edit]
The prognosis for patients with PMBCL has improved significantly with modern treatment regimens. The overall survival rate is favorable, particularly for patients who achieve complete remission after initial therapy.
